Nestlé has announced that it has completed the acquisition of Aimmune Therapeutics, Inc., the maker of peanut allergy treatment, Palforzia.
Aimmune Therapeutics will be a part of Nestlé Health Science (NHSc) as a stand-alone business unit and continue to operate from Brisbane, California.
In August of this year, Nestlé offered $2 billion (€1.7 billion) to gain full ownership of the California-based biopharmaceutical company.
An Important Milestone
Greg Behar, CEO of NHSc, commented, “Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-based nutritional solutions to support healthier lives.
"Aimmune's Palforzia, the first medication approved for treating peanut allergy, is a game-changer and it is only the beginning. Aimmune's pharmaceutical expertise and infrastructure will complement our existing research and development to further drive growth globally."
Nestlé added that Andrew Oxtoby will step in as the president and CEO of Aimmune along with a new executive leadership team.
Previously, Oxtoby served as Aimmune's chief commercial officer.
Development Programme
The development programme for Aimmune, which comprises the potential use of the treatment in toddlers and adults, multiple clinical development programmes in other allergies, and the development of the monoclonal antibody AlMab7195, will proceed as planned, Nestlé said.
In January 2020, the US Food and Drug Administration (FDA) approved Palforzia as oral immunotherapy for allergic reactions from accidental exposure to peanut in patients aged 4 through 17 years, with a confirmed diagnosis of peanut allergy.
In Europe, Aimmune's marketing authorisation application for the treatment is currently under review with the European Medicines Agency (EMA).
© 2020 European Supermarket Magazine – your source for the latest retail news. Article by Dayeeta Das. Click subscribe to sign up to ESM: The European Supermarket Magazine.
